// App-Quantinova.ai

: Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study

Researchers

Presenter

  • Stephanie Roseti

Principal Investigators

  • Jonathan Corren

  • Jane Parnes

  • May Mo

  • Janet Griffiths

  • Liangwei Wang

  • Rene Van Der Merwe

Medical Centers

  • MedImmune LLC, Gaithersburg, MD, United States of America

  • UCLA School of Medicine, Dermatology, Los Angeles, United States of America

  • Amgen Inc., Thousand Oaks, California, United States of America

  • MedImmune, Cambridge, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Tezepelumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02054130

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved